05:34 PM EDT, 10/16/2024 (MT Newswires) -- ACADIA Pharmaceuticals ( ACAD ) said late Wednesday that Health Canada has granted marketing authorization for Daybue, or trofinetide, to treat Rett syndrome in adult and pediatric patients aged two years and above.

The company is looking forward to bringing the treatment to Canadian patients "as soon as possible," Chief Executive Catherine Owen Adams said.

Rett syndrome is a rare neurodevelopmental disorder that mainly affects females.

Price: 15.15, Change: +0.11, Percent Change: +0.73